

Symposium "Frontiers in Medicinal Chemistry"

February 28th, 2011 | 9:00

TUM-IAS Auditorium | Lichtenbergstr. 2 a | Garching

09:00 Opening	Günther Wess CEO and President, Helmholtz Zentrum München
09:10 - 10:00	Herbert Waldmann (MPI Dortmund) "Are there novel cancer targets in the Ras signaling pathway?"
10:00 - 10:40	Matthias Urmann (Sanofi-Aventis) "New Treatment Possibilities in Diabetes"
10:40 - 11:10	<i>Coffee Break</i>
11:10 - 11:50	Trixi Brandl (Novartis, Basel) "Proteases in Medicinal Chemistry"
11:50 - 12:30	Andrew Thomas (FRSC, Roche) "Discovery of RG1678: A potent and selective GlyT1 inhibitor (GRI) for the treatment of Schizophrenia"
12:30 - 13:30	<i>Lunch</i>
13:30 - 13:40	Wolfgang A. Herrmann President, Technische Universität München
13:40 - 14:30	Stephen W. Fesik (Vanderbilt University, USA) "Cancer Drug Discovery Using Fragment-Based Methods"
14:30 - 15:00	<i>Coffee Break</i>
15:00 - 15:40	Franz von Nussbaum (Bayer Schering) "Discovery of Riociguat"
15:40 - 16:20	Henning Priepke (Boehringer Ingelheim) "Structure based design of coagulation inhibitors"
16:20 - 16:30	Horst Kessler Technische Universität München, Institute for Advanced Study
16:30	End of the Symposium